Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892123 · ClinicalTrials.gov registry record · Phase 1
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 279
- Enrollment target
NCT02892123 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 279 participants.
The verdict
NCT02892123, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 279 participants
- Enrollment target
Study Summary
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
Interventions
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Tucatinib
- DRUG Vinorelbine
- DRUG ZW25 (Zanidatamab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02892123
The ClinicalTrials.gov registry entry for NCT02892123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02892123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02892123 about?
NCT02892123 is a clinical study titled "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers". This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressi...
What is the current status of trial NCT02892123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 279 participants. The study started on 2016-09-30. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT02892123?
The interventions under investigation include: Capecitabine (DRUG), Paclitaxel (DRUG), Tucatinib (DRUG), Vinorelbine (DRUG), ZW25 (Zanidatamab) (DRUG).
Who is sponsoring clinical trial NCT02892123?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.